Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

1 hour ago 1

ARTICLE AD BOX

Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.

Read Entire Article

Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

ARTICLE AD BOX

Related

Investors were braced for an AI fallout — just not this one,...

Lilly says Mounjaro and Zepbound sales grew by at least 110%...

Gold’s back over $5,000 and silver’s surging as well

Trending

Popular

Can Pidcock win big & why did it end at Ineos?

‘I didn’t want to spend time with my children. I was just go...

‘Slanted’ Review: Extreme Makeover Satire Critiques Lopsided...

Netflix scuttles plans to add six previously announced games...

OpenAI co-founder John Schulman has left Anthropic after les...